INDOCO REMEDIES LIMITED
Location
Maharashtra
Founded
1947-08-23
Website
Risk Signals
87 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about INDOCO REMEDIES LIMITED
Live alerts from global media, monitored by Business Radar
2025-07-07 (equitymaster.com)
ACUTAAS CHEMICALS vs INDOCO REMEDIES - Comparison Results
Make stock comparison and analysis on (543349 | AMIORG~EQ) with Indoco Remedies (532612 | INDOCO~EQ) online at Equitymaster.
Read more
2025-05-22 (cnbctv18.com)
Indoco Remedies Q4 Results: Shares fall 7% as company reports loss, revenue drops 12% - CNBC TV18
Following the earnings announcement, shares of Indoco Remedies saw sharp fall. The stock fell over 12% from its day's high of ₹273.75 to hit a low of ₹240.25. As of 3:13 PM, the stock was trading at ₹242.40 on the BSE, down 7% for the day.
Read more
2024-09-09 (economictimes.com)
Stock Radar | Trendline breakout from declining channel makes Indoco Remedies an attractive buy: Shitij Gandhi - Video | ET Now
"Indoco Remedies stock has given a fresh breakout above the inverted head & shoulder pattern on short-term charts while trend line breakout above the declining channel has also been observed on broader charts with rising volumes. Traders can buy for a target of Rs 425-430 in the next 5-7 weeks," Shitij Gandhi, Senior Technical Analyst, SMC Global Securities, said.
Read more
2024-01-24 (ndtvprofit.com)
Indoco Remedies Q3 Results Review - Another Quarter Of Weak Margins: Prabhudas Lilladher
Indoco Remedies Ltd.'s cut our FY25/FY26 earning per share by ~10%/4% to factor in low margins and lower sales across regulated markets. We downgrade stock from Buy to 'Accumulate' given weak earnings visibility, muted domestic formulation sales. Our numbers do factor in margin recovery with reduction in remediation cost from FY25. Indoco Remedies Q3 FY24 Ebitda was sharply below our estimates led by continued higher remediation cost and lower regulated market sales.
Read more
2020-09-12 (zeebiz.com)
Mid-cap Picks With Anil Singhvi: JBM Auto, Indoco Remedies, Thyrocare are stocks to buy for high returns
Mid-cap Picks With Anil Singhvi: Amid Indian stocks closely following Wall Street and other global stock markets, Zee Business Managing Editor Anil Singhvi has been busy recommending various stock picks with his panel of experts. Get more India News and Business News on Zee Business.
Read more
(marketsmojo.com)
Indoco Remedies Faces Significant Stock Decline Amid Broader Market Challenges
Indoco Remedies, a small-cap pharmaceutical company, has faced a notable decline in its stock price, underperforming against its sector. The company has experienced significant volatility and is trading below key moving averages, reflecting ongoing challenges. Year-to-date, its performance contrasts sharply with broader market trends.
Read more
(businesstoday.in)
Indoco Remedies Ltd Share Price Today, INDOCO Share Price NSE, BSE
Indoco Remedies Ltd Share price NSE, BSE today: check share/stock price of INDOCO, get live NSE/BSE stock price of Indoco Remedies Ltd with financial reports, peer comparisons, stock performance, about company, shareholding pattern, SWOT analysis on Business Today.
Read more